FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000853346> ?p ?o ?g. }

• W2000853346 endingPage "2487" @default.
• W2000853346 startingPage "2478" @default.
• W2000853346 abstract "BACKGROUND. Atrasentan is a potent, oral, selective endothelin-A (ETA) receptor antagonist that has clinical activity in patients with hormone-refractory prostate cancer (HRPC). In this article, the authors report the results from a phase 3, randomized, double-blind, placebo-controlled trial of atrasentan in patients with nonmetastatic HRPC. METHODS. Of 941 patients who had adequate androgen suppression and no radiographic evidence of metastases but rising prostate-specific antigen (PSA) levels, 467 patients were randomized to receive atrasentan at a dose of 10 mg, and 474 patients were randomized to receive placebo daily. The primary endpoint was the time to disease progression (TTP), which was defined as the onset of metastases. Secondary endpoints were the time to PSA progression, change in bone alkaline phosphatase (BALP) levels, PSA doubling time, and overall survival. RESULTS. There was a 93-day delay in the median TTP with atrasentan, but the difference from placebo in TTP was not statistically significant (P = .288). Large geographic differences in the median TTP were noted: in the US: The difference was 81 days longer with placebo; whereas, in non-US sites, the difference was 180 days longer with atrasentan. Atrasentan lengthened the PSA doubling time (P = .031) and slowed the increase in BALP (P < .001). The median survival was 1477 days with atrasentan and 1403 days with placebo. The most common adverse events associated with atrasentan were peripheral edema, nasal congestion, and headache, consistent with the vasodilatory properties of ETA receptor antagonists. CONCLUSIONS. Although the primary endpoint was not achieved, large regional differences in TTP were noted, suggesting that trial conduct may have influenced the results. The biologic activity was consistent with findings from other clinical trials of atrasentan in HRPC. Cancer 2008. © 2008 American Cancer Society." @default.
• W2000853346 created "2016-06-24" @default.
• W2000853346 creator A5001783218 @default.
• W2000853346 creator A5023548391 @default.
• W2000853346 creator A5031111261 @default.
• W2000853346 creator A5037387251 @default.
• W2000853346 creator A5038365482 @default.
• W2000853346 creator A5046276886 @default.
• W2000853346 creator A5046888497 @default.
• W2000853346 creator A5053749991 @default.
• W2000853346 creator A5066111206 @default.
• W2000853346 date "2008-11-01" @default.
• W2000853346 modified "2023-10-17" @default.
• W2000853346 title "Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer" @default.
• W2000853346 cites W1965734230 @default.
• W2000853346 cites W1968041830 @default.
• W2000853346 cites W1986266121 @default.
• W2000853346 cites W1989416152 @default.
• W2000853346 cites W1991486724 @default.
• W2000853346 cites W2001556361 @default.
• W2000853346 cites W2020830322 @default.
• W2000853346 cites W2023659903 @default.
• W2000853346 cites W2025925482 @default.
• W2000853346 cites W2042692879 @default.
• W2000853346 cites W2065771840 @default.
• W2000853346 cites W2080439368 @default.
• W2000853346 cites W2085960871 @default.
• W2000853346 cites W2120292596 @default.
• W2000853346 cites W2140061644 @default.
• W2000853346 cites W2151840803 @default.
• W2000853346 cites W2157205997 @default.
• W2000853346 cites W2164828052 @default.
• W2000853346 doi "https://doi.org/10.1002/cncr.23864" @default.
• W2000853346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3085548" @default.
• W2000853346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18785254" @default.
• W2000853346 hasPublicationYear "2008" @default.
• W2000853346 type Work @default.
• W2000853346 sameAs 2000853346 @default.
• W2000853346 citedByCount "224" @default.
• W2000853346 countsByYear W20008533462012 @default.
• W2000853346 countsByYear W20008533462013 @default.
• W2000853346 countsByYear W20008533462014 @default.
• W2000853346 countsByYear W20008533462015 @default.
• W2000853346 countsByYear W20008533462016 @default.
• W2000853346 countsByYear W20008533462017 @default.
• W2000853346 countsByYear W20008533462018 @default.
• W2000853346 countsByYear W20008533462019 @default.
• W2000853346 countsByYear W20008533462020 @default.
• W2000853346 countsByYear W20008533462021 @default.
• W2000853346 countsByYear W20008533462022 @default.
• W2000853346 crossrefType "journal-article" @default.
• W2000853346 hasAuthorship W2000853346A5001783218 @default.
• W2000853346 hasAuthorship W2000853346A5023548391 @default.
• W2000853346 hasAuthorship W2000853346A5031111261 @default.
• W2000853346 hasAuthorship W2000853346A5037387251 @default.
• W2000853346 hasAuthorship W2000853346A5038365482 @default.
• W2000853346 hasAuthorship W2000853346A5046276886 @default.
• W2000853346 hasAuthorship W2000853346A5046888497 @default.
• W2000853346 hasAuthorship W2000853346A5053749991 @default.
• W2000853346 hasAuthorship W2000853346A5066111206 @default.
• W2000853346 hasBestOaLocation W20008533462 @default.
• W2000853346 hasConcept C121608353 @default.
• W2000853346 hasConcept C126322002 @default.
• W2000853346 hasConcept C126894567 @default.
• W2000853346 hasConcept C142724271 @default.
• W2000853346 hasConcept C168563851 @default.
• W2000853346 hasConcept C185592680 @default.
• W2000853346 hasConcept C197934379 @default.
• W2000853346 hasConcept C202751555 @default.
• W2000853346 hasConcept C203092338 @default.
• W2000853346 hasConcept C204787440 @default.
• W2000853346 hasConcept C27081682 @default.
• W2000853346 hasConcept C2776235491 @default.
• W2000853346 hasConcept C2777482430 @default.
• W2000853346 hasConcept C2780192828 @default.
• W2000853346 hasConcept C2781406297 @default.
• W2000853346 hasConcept C48900799 @default.
• W2000853346 hasConcept C55493867 @default.
• W2000853346 hasConcept C71924100 @default.
• W2000853346 hasConceptScore W2000853346C121608353 @default.
• W2000853346 hasConceptScore W2000853346C126322002 @default.
• W2000853346 hasConceptScore W2000853346C126894567 @default.
• W2000853346 hasConceptScore W2000853346C142724271 @default.
• W2000853346 hasConceptScore W2000853346C168563851 @default.
• W2000853346 hasConceptScore W2000853346C185592680 @default.
• W2000853346 hasConceptScore W2000853346C197934379 @default.
• W2000853346 hasConceptScore W2000853346C202751555 @default.
• W2000853346 hasConceptScore W2000853346C203092338 @default.
• W2000853346 hasConceptScore W2000853346C204787440 @default.
• W2000853346 hasConceptScore W2000853346C27081682 @default.
• W2000853346 hasConceptScore W2000853346C2776235491 @default.
• W2000853346 hasConceptScore W2000853346C2777482430 @default.
• W2000853346 hasConceptScore W2000853346C2780192828 @default.
• W2000853346 hasConceptScore W2000853346C2781406297 @default.
• W2000853346 hasConceptScore W2000853346C48900799 @default.
• W2000853346 hasConceptScore W2000853346C55493867 @default.
• W2000853346 hasConceptScore W2000853346C71924100 @default.
• W2000853346 hasIssue "9" @default.

• next